What’s Now and What’s Next
In a year of change, Johnson & Johnson Innovation supported the global innovation ecosystem to adapt and pivot to continue addressing high unmet needs across all areas of health. The company enables and accelerates early scientific discoveries by investing in and partnering with innovators with the potential to positively impact human health.
This month, Johnson & Johnson will return virtually to the 39th Annual J.P. Morgan Healthcare Conference 2021 and J.P. Morgan Week, coming together with industry leaders, emerging innovators and members of the investment community to drive forward potential health solutions.
Deals around the world
|
Innovation through Collaboration |
|
Accelerating Innovation Worldwide: Company Brochure |
A Vision for the Breakthroughs of Tomorrow
Leading up to and during the events on January 11-14, live and on-demand programming sessions featuring Johnson & Johnson leadership will take place.
Alex Gorsky, Chairman and Chief Executive Officer and Joseph J. Wolk, Executive Vice President and Chief Financial Officer
J.P. Morgan Healthcare Conference session
 Ruxandra Draghia Akli, Global Head, Global Public Health R&D, The Janssen Pharmaceutical Companies of Johnson & Johnson |
 Marian Nakada, Vice President, Venture Investments, Johnson & Johnson Biotech Showcase – Value Creation and Venture
|
 Mathai Mammen, MD, PhD, Global Head of Research and Development at Janssen |
 Susan Morano, Vice President, Business Development, Johnson & Johnson Medical Devices |
 Orlando Serani, Program Architect CAR-T Advanced Cell Therapies Supply Chain, Janssen Pharmaceutical Companies of Johnson & Johnson McDermott & EY – Life Sciences Investment Forum, Cell and Gene Therapies |
 Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson |
 Stephen Pitt, Ph.D., Head of Johnson & Johnson Innovation – JLABS US North East |
 Stacy Feld, Head, Johnson & Johnson Innovation, West North America, Australia & New Zealand |
 Michal Preminger, Ph.D., MBA, Head, Johnson & Johnson Innovation, East North America |
 Sally Allain, Head of JLABS @ Washington DC |
Pushing the limits of the ‘speed of science’
Closing over 100 deals in 2020, Johnson & Johnson continued to help global innovators to adapt and thrive in a year of change.
Check back throughout the week to hear from our team and our partners on how partnering with Johnson & Johnson can help drive scientific discovery and acceleration, through special JPM 2021 coverage.
Connect with us at JPM 2021 |
Subscribe to our newsletter |